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Summary
The bactericidal/permeability-increasing protein (BPI) ofpolymorphonuclear leukocytes (PMN)
is a potent cytotoxin, specific for Gram-negative bacteria, that also inhibits endotoxin activity
by neutralizing isolated bacterial lipopolysaccharides (LPS) . We have previously shown that an
isolated 25 kD N-terminal fragment ofhuman BPI carries all the antibacterial activities of the
parent 55-60 kD molecule . In this study we have compared the LPS-neutralizing activities of
human holo-BPI, the N-terminal fragment and a 30 kD C-terminal fragment that we have now
isolated. We show that the N-terminal fragment also has LPS-neutralizing activity as detected
by inhibition (up to 95%) of (a) activationbyLPS ofprocoagulant proteases in Limulusamebocyte
lysates, (b) LPS "priming" ofPMN, and (c) LPS-mediated production of tumor necrosis factor
in whole human blood. Holo-BPI and the 25 kD fragment have similar neutralizing potency
(in nanomolar range) in all assays toward "smooth" LPS from Escherichia coli 0111:B4 and 055:B5
(possessing long chain polysaccharide or 0-antigen), and "deep rough" LPS from Salmonella
minnesota 8,595 mutant (possessing no 0-antigen) . The C-terminal fragment of BPI is devoid
of antibacterial activity when tested against BPI-sensitive E. coli J5, but does have endotoxin-
neutralizing activity. This activity is weak relative to holo-BPI and the 25 kD N-terminal fragment
in the Limulus and PMN-priming assay, but is comparable for inhibition of TNF production
in whole blood. We conclude that the principal determinants for LPS recognition and neutralization,
like those for antibacterial action, reside in the N-terminal half of the BPI molecule, but that
sites within the C-terminal half can also contribute to BPI-LPS interaction once LPS is detached
from the bacterial envelope .
E
ndotoxins, complex LPS that are major components of
the outer envelope of Gram-negative bacteria, can ac-
count for the most serious clinical consequences of Gram-
negative bacterial infections (1) . At concentrations as low as
subnanogram-to-ng/ml these agents elicit in the host many
cellular and extracellular responses that include the produc-
tion and release of a diverse network of mediators such as
activated Complement components, cytokines (e.g ., tumor
necrosis factor, interleukins) and arachidonate metabolites (2) .
While these reactions must have evolved as part of essential
host defenses, they may also become excessive and self-
destructive (1-3), prompting many attempts to attenuate host
responses to LPS. Recent reports indicate life-saving effects
ofmAbs, directed against the biologically active lipid A por-
tion of the LPS molecule, in patients with Gram-negative
bacteremia and sepsis (4-6) in accord with a primary role
of endotoxin in the pathogenesis of Gram-negative sepsis and
supporting the potential clinical usefulness ofanti-LPS directed
therapies .
Progress has also been made in the identification and char-
acterization of endogenous LPS-binding proteins, produced
by various cells and tissues (7-11), thatmay mediate and regu-
late the response of the host to LPS. Among these proteins
is an LPS-binding protein (LBP)t that is produced and
secreted by the liver and that accumulates in plasma at >100
x higher than baseline concentrations during the acute phase
response that is triggered by LPS and other irritants (10) .
Abbreviations used in thispaper . BPI, bactericidal/permeability-increasing
protein ; LBP, lipopolysaccharide binding protein; LTB4, leukotriene B4 .
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cells to macrophages andmagnifies responses of macrophages
andPMN to LPS (12-14), suggesting that the function of
LBP is to heighten the host's response to LPS. In contrast,
a related LPS-binding protein, the bactericidal/permeabil-
ity-increasing protein (BPI) of PMN (14, 15), suppresses
endotoxin-mediated activation of procoagulant protease(s) in
Limulus amebocyte lysates andupregulation ofCR1 andCR3
receptors on the surface ofPMN (16) . Together with its po-
tent antibacterial properties (17, 18), these findings suggest
that BPImaybe able to downregulate responses toLPSboth
by halting the proliferation of bacteria producing LPS and
by directly inhibiting LPS itself.
A striking property ofBPI is its selective cytotoxicity for
Gram-negative bacteria (17-19), which reflects the avid and
specific affinity ofBPI for the Gram-negative bacterial sur-
face, and is best explained by a strong attraction of the posi-
tively charged protein for the negatively charged LPS in the
bacterial outer membrane (20-22) . We have shown before
that the antibacterial activities and therefore the extraordi-
nary affinity of BPI for Gram-negativebacteria reside entirely
within a highly cationic 25 kD N-terminal fragment (23,
24) . However, in the case of interactions with cell-freeforms
ofLPS in which the lipidAregion is notburied in an intact
outer membrane, additional interactions with hydrophobic
sites in the C-terminal portion (23, 24) of BPI may also be
involved . It should be noted that the homology between BPI
and LBP (approx. 45% overall sequence identity) extends
throughout thewhole 55-60 kD molecules (14), further sug-
gesting that thedeterminants of protein-LPS interactionmay
not be entirely limited to the N-terminal region . We now
report theisolation of aca . 30 kD C-terminal BPI fragment
and describe further the functional properties of holo-BPI
and its N- and C-terminal fragments . Our findings demon-
strate that thepotent endotoxin-neutralizing activity of BPI
is conferred mainly but not solely by the N-terminal frag-
ment . This activity is manifest both in physiological salt so-
lution and in whole blood indicating that BPI or fragments
of BPI may suppress endotoxin activity in vivo .
Materials and Methods
Materials .
￿
Purified LPS fromE . coli055:135 (S chemotype) was
obtained from Calbiochem Corp. (La Jolla, CA) and resuspended
in pyrogen-free water with vigorous vortexing according to the
instructions of Whittaker_Bioproducts, Inc . (Walkersville, MD).
Serial dilutions of LPS, were prepared in the same way and stock
solutions ofLPS (10 ng/ml) were stored at 4°C.LPSfromSalmonella
minnesota mutant R. 595 (R, chemotype) was obtained from List
Biologicals (Campbell, CA). Solutions of this LPS were prepared
by sonication as previously described (25) . Thechromogenic Limulus
amebocyte lysate assay kitwas from Whittaker Bioproducts, Inc .,
and zymosanwasfrom SigmaChemical Co . (St . Louis, MO). Leu-
kotriene B4 (LTB4) standards were from Calbiochem Corp. (LTB4)
and Biomol (LTB4-OH) . Tumor necrosis factor (N4 x 107 U/mg)
wasthekind gift ofDrs . J . Le andJ. Vilcek(New York University
Medical Center, New York, NY). Hanks' buffered salts solution
(minus Cat' and Mg*) (HBSS-) was from Gibco Laboratories
(Grand Island, NY). Acetonitrile wasfromJ .TBaker, Inc. (Philips-
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burg, NJ), trifluoroacetic acid from Pierce Biochemicals (Rockford,
IL), and bovine serum albumin from United States Biochemical
Corp . (Cleveland, OH). The Bio-Rad protein assay kit was from
Bio-Rad Laboratories (Richmond, CA), and nitrocellulose was from
Schleicher&Schuell, Inc. (Keene, NH) . Nutrient brothandBiTek
agar were from Difco Laboratories (Detroit, MI) .
Polymorphonuclear Leukocytes. Polymorphonuclear leukocytes
were isolated from the venous blood of normal volunteers using
standard procedures of dextran sedimentation and centrifugation
on Ficoll-Hypaque as previously described (26) .
Purification ofHuman BPI and its 25 hDa NHZ-Terminal Frag-
ment. Human BPIwas purified from crude extracts of PMN-rich
populations using E. coli as an affinity matrix, as previously de-
scribed (22) . The 25 kD NH Z-terminal fragment of human BPI
was isolated after limited proteolysis of purified human BPI as de-
scribed before (23) .
Reversed-Phase High Performance Liquid Chromatography (HPLC).
Reversed-phase HPLC was carried out on a reversed-phase Vydac
C4 column (The Separations Group, Hesperia, CA) using a Beck-
man HPLC system model332 (Beckman Instruments, Inc., Some-
rset, NJ) . A linear gradient of acetonitrile in 0.1% (v/v) trifluo-
roacetic acid was developed at a flow rate of 1 ml/min (see legend,
Fig . 1) . Elution of protein wasmonitoredby absorbance at 214 rim .
Eluted proteins were immediately dialyzed against 50 volumes of
10-50mM sodium acetate,pH 4.0 . All protein sampleswere stored
at 4°C .
Western Blot.
￿
SDS-PAGE of proteins (12% polyacrylamide gel
system of Laemmli), transfer ofproteins to nitrocellulose, and im-
munodetection of proteins with rabbit anti-BPI/['ZS-I1-Protein G
was carried out as previously described (27-29) .
Determination ofProtein Mass.
￿
Protein mass was estimated by
the Bio-Rad protein assay kit andby absorbance at 280nm, with
bovine serum albumin as the standard . Protein estimates were
confirmed by Coomasie blue staining after SDS-PAGE .
NHZ-Terminal Amino Acid Sequencing. NHZ-terminal amino
acid sequence analyses were performedby sequentialEdman degra-
dation on an Applied Biosystems 470A (Applied Biosystems, San
Francisco, CA).
Bacterial Cultures.
￿
E . coliJ5,a"rough" (short-chain LPS) UDP-
4-galactose-epimeraseless mutant of the "smooth" (long-chain LPS)
parentE . coli 0111:134, was grown overnight, and then in subcul-
ture at 37°C in triethanolamine-buffered medium (20) . Bacterial
subcultures were harvested at mid-logarithmic phase and resus-
pended to the desired concentration in sterile physiological saline .
Bioassays
Bacterial Growth Inhibition .
￿
Bacteria were incubatedwith pro-
tein to be tested for 15 min at 37°C in the standard incubation
mixture containing 0.8% (w/v) nutrient broth in saline buffered
with 20 mM sodium phosphate pH 6.0 . After the incubation, bac-
teria were serially diluted with sterile physiological saline to 4 x
10, organisms/ml, then plated on nutrient agar (0.8% (w/v) nu-
trient broth, 0.5% (w/v)NaCl, 1.5% (w/v)/BiTek agar)by pouring
5 ml molten nutrient agar (48°C) into a sterile petri dish containing
30 p,l of the diluted bacteria . Bacterial growth was measured as
the number of colony forming units enumerated after overnight
incubation at 37°C .
Bacterial Outer-Membrane Permeability-Increasing Activity.
￿
Perme-
ability of the E. coli outermembrane to thenormally impermeant
actinomycinD was assessed by measuring sensitivity of bacteria
to actinomycin D added to a final concentration of 50 ug/ml in
the standard incubation mixture . After incubation for 15 min at
37° C, bacterial growth was measured as described above (30) .LPS-neutralization by BPI
For the Limulus amebocyte lysate and the PMN priming assays,
LPS was pre-incubated with or without BPI(fragments) in poly-
propylene tubes, in 10 mM sodium phosphate, pH 7.0 or in HBSS
(minus Ca" and Mgt+), for 15-30 min at 37°C. For the TNF-
release assays, BPI or fragments were added to whole blood to the
desired final concentrations, followed within 5 min by LPS. Pro-
teins and LPS were added in HBSS, each representing 5% of the
final incubation volume (0.25 ml).
Chromogenic Limulus Amebocyte Lysate Assay.
￿
LPS-triggered pro-
tease activity in Limulus amebocyte lysates was measured using a
chromogenic Limulus amebocyte lysate kit, following the instruc-
tions supplied.
LPS Priming ofPMN Response to Opsonized Zymosan.
￿
The re-
lease of leukotriene B4 (LTB4) (and its metabolites) by PMN in
response to opsonized zymosan after LPS priming was measured
as previously described (25). LPS from S. minnesota mutant R, 595
in 0.5 ml was added to an equal volume of PMN suspension (in
HBSS-) (5 x 106 PMN) and incubated for 45 min at 37°C in
a shaking water bath. Following incubation, Cal' and Mgz+ salts
were added to a final concentration of 1.25 and 0.4 mM, respec-
tively (representing amounts present in HBSS+). Opsonized
zymosan was added (5 mg/ml) and the mixture was incubated for
an additional 45 min at 37°C in a dry bath. Incubations were ter-
minated by addition of 1.5 volumes of iced ethanol (with 200 ng
prostaglandin 132/sample as an internal standard) and extracts were
prepared as previously described (25). LTB4 and metabolites were
separated using a Waters HPLC system (Waters/Millipore, Mor-
ristown, NJ), and identified and quantitated by comparison to ap-
propriate standards (31).
LPS-InducedRelease ofTumorNecrosis Factorin Whole Blood.
￿
LPS-
triggered release of TNF in whole blood ex vivo was carried out
as described by Desch et al. (32) except that blood was collected
into tubescontainingcitrate as an anti-coagulant (Becton-Dickinson,
Lincoln Park, NJ). Blood samples were incubated for 6 h at 37°C.
After dilution ofblood 4 x with RPMI, the extracellular medium
was collected by centrifugation at 500 g. TNF in the recovered
medium was measured by ELISA using the Biokine TNF test kit
(T Cell Sciences, Cambridge, MA).
Results
Purification ofca. 30 kD CTerminal Fragments)
ofHuman BPI
To permit a more complete assessment of the structural
and functional properties of human BPI, we sought to iso-
late the C-terminal portion of the protein. During the limited
proteolysis that generates the active 25 kD N-terminal frag-
ment, similar amounts of a ca. 30 kD species also accumu-
late (23) . Whereas the 25 kD fragment was readily isolated
from the digest by reversed-phase HPLC, the ca. 30 kD spe-
cies coeluted with the holo-protein (23). However, rechro-
matography using a shallower acetonitrile gradient allowed
separation of the 60 kD and ca. 30 kD protein species (Fig. 1).
The peak eluting earlier comigrated with the 60 kD species
upon SDS-PAGE (not shown), and the later peak migrated as
a slightly heterogeneous ca. 30 kD species (Fig. 1). N-terminal
amino acid sequence analysis of the latter protein fraction re-
vealed the presence of two overlapping species: (a) Asp-Ser-
Val-(
￿
)-Gly-Ile-AsnTyr-Gly-Leu-Vat, and (b) Ala-Gly-Ile-(
￿
)-
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￿
Purification ofa ca. 30 kD fragment ofhumanBPI byreversed-
phaseHPLC.Chromatography wascarried out as described underMaterials
and Methods. The (broken line) indicates the gradient of acetonitnle; the
(solid line) indicates elution of material absorbing at 214 nm. (Leftpanel)
shows rechromatography of the protein (-100 jug) from the peak con-
taining both holo-BPI and the ca. 30 kD species (20); (rightpanel) shows
rechromatography of purified ca. 30 kD fragment(s) (-25-Kg). Inset in
(right panel) shows Western blot of the purified 30 kD fragment(s) (see
Materials and Methods), with numbers indicating migration of protein
mol wt standards.
Tyr-Gly-LeuVal-Ala-Pro, corresponding to the sequence of
BPI starting respectively from residues 200 and 204 (24). The
size and location of the 30 kD fragments indicate therefore
that they represent the C-terminal half of the BPI molecule.
The greater hydrophobicity of this portion of BPI explains
the later elution of the 30 kD fragments during reversed-
phase HPLC.
In contrast to the 25 kD N-terminal fragment, the purified
C-terminal fragment(s) displayed no antibacterial activity to-
ward BPI-sensitive E. coli. The C-terminal fragment(s) pro-
duced neither growth inhibitory nor outer membrane
permeability-increasing effects on E. coliJ5, even when tested
at doses thirty times higher than an effective dose of the 25
kD fragment (Fig. 2) .
Comparison of the antibacterial activities of BPI and its
two fragments confirms our previous findings showing that
the antibacterial activities of BPI can be accounted for en-
tirely by a region within the 25 kD N-terminal fragment.
To determine which portion(s) of BPI is (are) required for
endotoxin neutralization, we measured the effects on endo-
toxic activity of holo-BPI and the N- and C-terminal frag-
ments in three different settings of LPS-mediated responses:
(a) Activation of proteases in Limulus amebocyte lysates; (b)
Priming of arachidonate metabolism by PMN; (c) Induction
of TNF production in whole blood ex vivo.
Limuks Amebocyte LywteAssay.
￿
Pre-incubation of"smooth"
LPS (from E. coli 0111:134 or 055:135, S chemotype) with
holo-BPI produced a dose-dependent inhibition of the acti-V
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￿
Comparison of antibacterial activities of the 25 kD N-terminal
and the ca . 30 kD C-terminal fragments . E. coli J5 (5 x 106) were in-
cubated in the standard incubation mixture (see Materials and Methods)
(125 Al) with increasing amounts of the 25 kD fragment (--W-) or the
ca . 30 kD fragment in the absence (--&-) or presence (-0-) of ac-
tinomycin D (50 ag/ml) . Growth inhibitory effects (closed symbols) were
measured by assessing colony formation on nutrient agar. Since the ca .
30 kD fragment did not show any growth inhibitory effect, outer mem-
brane permeability-increasing effects (open symbols) could be assessed by
measuring bacterial viability in the presence of actinomycin D. The data
are presented as percent of values obtained for bacteria incubated alone,
and are the mean of two similar experiments.
vation by LPS ofprotease(s) in Limulus amebocyte lysates (Fig. 3
a) . Inhibition was nearly complete at 10 nM BPI in accord
with the report of Marra et al . (16) . Maximum inhibition
required pre-incubation ofBPI with LPS for 20-30 min (data
not shown) . The endotoxin-neutralizing activity of the 25
kD N-terminal fragment was nearly the same as that ofholo-
BPI . The 30 kD C-terminal fragment also inhibited endo-
toxin, but at 5-10-fold higher molar protein concentrations
(Fig. 3 a) .
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Figure 3 .
￿
Inhibition ofLPS-mediated activation ofLimulus amebocyte
proteases by human BPI and its N- and C-terminal fragments . LPS from
E. coli 055:B5 (1 ng/ml) (a), or S. minnesota mutant Re 595 (0.6 or 2
ng/ml) (b), were pre-incubated with increasing amounts of human BPI
(-0-), 25 kD N-terminal fragment (-A-), or ca . 30 kD C-terminal
fragment(s)
￿
Preincubations were in 10 mM sodium phosphate
buffer, pH 7 .0 (a) or HBSS (minus Ca2 * and Mg2 +) (b) at 37°C for 15
min . The LPS-protein incubation mixtures were then diluted to giveLPS
concentrations of 0 .1 ng/ml (a), or 0.03 ng/ml (b) for measurement of
LPS activity in the Limulus assay as described in Materials and Methods .
Both holo-BPI and the 25 kD fragment also inhibited ac-
tivation of proteolysis in the Limulus assay by "rough" LPS
from S. minnesota (Re595 LPS) . The 30 kD fragment, how-
ever, showed onlyweak LPS-neutralizing activity (Fig . 3 b) .
Priming ofPMN.
￿
Pretreatment ofPMN withLPS causes
a dose-dependent increase in release of leukotriene B4 (LTB4)
and its metabolites during subsequent incubation ofthe primed
PMN with opsonized zymosan (reference 25 ; Fig . 4 a) .
Pretreatment for 15 min ofRe595 LPS with either holo-BPI
or the 25kD fragment suppressed, in dose-dependent fashion,
this primed PMN response (Fig . 4 b) . The two protein spe-
cies caused suppression of endotoxin activity by 50 percent
at respectively 1.0 and 0.3 nM and nearly complete inhibi-
tion at 10 nM concentrations of each protein . In contrast,
the 30 kD C-terminal fragment(s) did not inhibit priming.
Neither holo-BPI nor its fragments reduced the basal response
ofPMN to opsonized zymosan (data not shown) . The inhi-
bition of priming by BPI and the N-terminal fragment was
apparently attributable to a direct effect on endotoxin be-
cause : (a) Pretreatment ofPMN with BPI and washing be-
fore addition ofLPS did not inhibit priming ; and (b) priming
ofPMN by tumor necrosis factor (1 ng/ml) was unaffected
by BPI (reference 16; data not shown) .
TNFProduction in Whole Human Blood.
￿
To determine if
the potent endotoxin-neutralizing effects of BPI (and frag-
ments), evident in a medium of artificial composition, can
80 .
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￿
Effect of holo-BPI and its N- and C-terminal fragments on
priming of PMN by LPS. Priming of PMN by Re 595 LPS was deter-
mined by measuring the release of LTB4 (and metabolites) in response to
opsonized zymosan after pre-incubation ofPMN with LPS, as described
in Materials and Methods. The amount ofLTB4 (and metabolites) released
by unprimed cells (i.e., preincubation with buffer alone) was subtracted
from the actual amount of LTB4 (and metabolites) released, to yield the
amount of LTB4 (and metabolites) released as a result of LPS priming.
(a) Release of LTB4 (and metabolites) was measured after preincubation
ofPMN with varying amounts of 8.595 LPS. Priming of 5 x 106 PMN
by 1 .0 ng/ml LPS resulted in release of 32.0 ± 4 .5 ng LTB4 and metabo-
lites (n - 4), representing an enhancement of 5-10-fold over unprimed
cells. Values are expressed as % ofmaximum release, which is defined as
amount of LTB4 released in response to 1 ng/ml LPS. (b) LPS (0 .6 or
2 ng/ml) was pre-incubated alone or with the indicated concentrations
of holo-BPI and the N- and C-terminal fragments at 37°C for 15 min
before adding LPS to thePMN suspension (final LPS concentration 0.3
or 1.0 ng/ml) . The effect ofadded protein was thesame atboth LPS doses,
and therefore these data are pooled . Values are expressed as % LPS ac-
tivity, as calculated using the LPS standard curve shown in (a) . Each value
shown represents the z ± SEM of eight more determinations .Figure 5.
￿
Inhibition by holo-BPI and its N- and C-terminal fragments
ofLPS-triggered TNF accumulation inwhole blood . (a) Effect ofincreasing
concentrations ofR. 595 LPS on TNF accumulation in whole blood . (b)
Effect ofincreasing concentrations ofholo-BPI and its 25 kD N-terminal
and 30 kD C-terminal fragments on ability ofR. 595 LPS (1 ng/ml) to
induce accumulation ofTNF in whole blood . LPS activity was calculated
as described in the legend to Fig . 4. Each value shown represents the
z ± SEM of six or more determinations.
also be elicited in the complex environment of whole blood
with its content of other LPS-binding proteins such as LBP
and lipoproteins, we examined the effect of the proteins on
the production ofTNF in whole blood after incubation with
LPS (32) . Addition ofLPS to whole blood triggers a dose-
dependent synthesis and extracellular release ofTNF (refer-
ence 32 ; Fig. 5 a) . Addition ofhuman BPI to whole human
blood before adding Re595 LPS caused a dose-dependent in-
hibition ofTNF accumulation, over at least a 30-fold range
ofLPS doses (0.1-3 ng/ml) . At 1 ng/ml LPS, TNF produc-
tion was inhibited by 50% at a BPI concentration of 4 nM
and by ca. 90% at ca. 30 nM (Fig. 5 b) . As in the Limulus
and the PMN-priming assays, the concentration dependence
of the neutralizing activity of the 25 kD N-terminal frag-
ment was of the same order as that of holo-BPI, i .e. : 50%
Table 1.
￿
BPI (Fragments) Do Not Inhibit TNF Production in
Whole Blood Triggered by Heat-killed S . aureus
Protein added
Holo-BPI
-~ N-rcmunelfngment
- C-mminelfngmem
Protein (nM)
Release ofTNF in whole blood was measured as described in Methods .
Protein amounts were 33 nM holo-BPI, 40nM 25 kDa N-terminal frag-
ment, and 33 nM 30 kDa C-terminal fragment .
NT, not tested .
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inhibition at 12 nM and nearly 90% at 40 nM . However,
in contrast to the weaker endotoxin-neutralizing activity in
the preceding assays, the potency of the 30 kD C-terminal
fragment(s) as inhibitor ofTNF production falls in the same
range (50% inhibition at 15 nM protein and ca. 80% at ap-
proximately 30nM) as shown for holo-BPI and the N-terminal
fragment (Fig . 5 b) . Full inhibitory effects did not require
preincubation of BPI (or fragments) with LPS . The proteins
alone had no recognizable effect on TNF production in re-
sponse to heat-killed S. aureus (Table 1) .
Discussion
Guided by the functional properties of an N-terminal 25kD
fragment obtained by limited proteolysis and the structural
properties of the holoprotein deduced from its primary struc-
ture, we have previously proposed that human BPI is orga-
nized into two domains linked via a protease-sensitive region,
with all of the determinants for the antibacterial activities
of BPI residing within the N-terminal half of the protein
(23, 24) .
The isolation and characterization of the ca . 30 kD frag-
ments) now reported provide further evidence supporting
this model . The N-terminal sequence of these fragment(s)
indicates that cleavages occur at peptide bonds between residues
199-200 and 203-204 during the limited proteolysis of BPI
that gives rise to both these fragment(s) and the antibacterial
N-terminal fragment (23) . Since the 25 kD (N-terminal) and
30 kD fragments are generated in roughly equal amounts
with no other fragments detected (23) these findings indi-
cate that the principal cleavages are restricted to the predicted
protease-sensitive region and that the C-terminal boundary
of the active N-terminal fragment does not extend beyond
residues 199 or 203 . The predicted (peptide) mass ofN- and
C-terminal fragments comprising residues 1-199(203) and
200(204)-456 (the C-terminus of BPI ; 24) is ca. 23 and 29
W, respectively, corresponding closely to the apparent Mr
ofthese fragments estimated from their migration rates during
SDS-PAGE . The small differences may reflect carbohydrate
content (24) . The absence of detectable (<5%) antibacterial
activity in the purified 30 kD fragments is consistent with
our previous conclusion that these activities reside entirely
within the N-terminal portion of BPI .
We conclude, therefore, that all of the molecular deter-
minants required for the specific and potent cytotoxicity of
BPI toward Gram-negative bacteria are present within the
region of the protein encompassed by residues 1-199 (203) .
It is the portion of the BPI molecule that is also closely
similar to holo-BPI in its activity as a neutralizing agent against
isolated LPS in three different assessments of LPS-activity in
vitro : (a) the limulus lysate test, (b) priming of neutrophils
for arachidonate metabolism, and (c) the production ofTNF
in whole blood. Thus, the principal determinants of LPS rec-
ognition and neutralization also reside within this region of
BPI . The strong attraction ofBPI as well as ofits N-terminal
fragment for LPS, whether embedded in the gram-negative
bacterial envelope or as isolated molecules, can be explained
Heat killed
S . aureus added
10'
None
1 .5
Holo-BPI
TNF
NT'
25 kD
fragment
produced :
NT
30 kD
fragment
ng/ml
NT
3 x 10' 3.8 4 .1 3.4 3.9
10, 7.2 7.1 7.0 6.2
3 x 108 11 .5 10.9 11.5 10.7by two structural features of this portion of the BPI mole-
cule : (a) The very high content ofbasic residues in BPI that
are concentrated in the N-terminal region (the net charge
of the region comprising residues 1-199 is +17) (20, 21, 24,
33) and (b) hydrophobic stretches in this region . The former
provides a strong electrostatic attraction to the cluster ofan-
ionic sites in the core region of LPS, while the latter can ac-
count for a hydrophobic interaction with the lipid A moiety
ofLPS (24, 34) . The finding that the C-terminal fragment
that lacks the charge properties for electrostatic attraction
to LPS (net charge -2 to -3), but that contains several prom-
inently hydrophobic regions (24), does not possess antibac-
terial properties but does exhibit LPS-neutralizing activity,
suggests that its hydrophobic properties are sufficient for LPS
recognition under certain conditions and therefore that regions
in the BPI molecule outside the N-terminal fragment can
also contribute to interaction with LPS . However, in con-
trast to the activities of the holo-BPI and the N-terminal frag-
ment that are the same or nearly the same under all condi-
tions tested, the LPS-neutralizing activity of the C-terminal
fragment varies greatly with the different endpoints exam-
ined . Thus, whereas the C-terminal fragment shows no in-
hibition of the priming of PMN by Re595 LPS, and very
limited neutralizing activity in the limulus assay (Fig. 3 b)
when the same "rough" LPS is the stimulus, with long chain
LPS the C-terminal fragment is clearly inhibitory, although
at molar concentrations that are much higher than of holo-
BPI or the N-terminal fragment (Fig. 3 a) . On the other
hand, the potency of the N-terminal and the C-terminal frag-
ments as inhibitors of the stimulation of TNF production
byLPS in whole blood is similar. Apparently, the highly vari-
able physical presentation ofLPS (34-36), depending on its
chemical structure and state of aggregation as well as environ-
mental factors such as ionic composition and neighboring
macromolecules, has a much more profound effect on the
LPS-interactive capabilities of the C-terminal fragment than
of holo-BPI and the N-terminal fragment . The extent ofLPS-
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neutralizing activity of the hydrophobic C-terminal fragment
may depend on the accessibility of the fatty aryl chains of
lipid A . These are shielded when LPS forms aggregates, es-
pecially in the case of "rough" LPS or within the hydrophobic
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In summary, our findings together with the earlier obser-
vations ofMarra et al . (16) demonstrate that BPI can inhibit
a number of LPS-dependent responses elicited by a variety
ofLPS. Although we have not yet demonstrated this directly,
it is most likely that both the endotoxin-neutralizing and
the antibacterial action ofBPI as well are initiated by binding
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that the biological consequences depend on more subtle and
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